Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
32.96
+0.73 (2.26%)
Aug 11, 2026, 4:00 PM EDT - Market closed
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $9.33M in the quarter ending June 30, 2026, a decrease of -32.51%. This brings the company's revenue in the last twelve months to $27.59M, down -86.20% year-over-year. In the year 2025, Stoke Therapeutics had annual revenue of $184.42M with 404.50% growth.
Revenue (ttm)
$27.59M
Revenue Growth
-86.20%
P/S Ratio
77.09
Revenue / Employee
$162,282
Employees
170
Market Cap
2.13B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184.42M | 147.87M | 404.50% |
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ADMA Biologics | 512.28M |
| Aurinia Pharmaceuticals | 311.51M |
| Agios Pharmaceuticals | 98.34M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 52.06M |
| Nanobiotix | 38.27M |
| Zenas BioPharma | 10.00M |
| Taysha Gene Therapies | 7.47M |
STOK News
- 6 days ago - Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Business Wire
- 7 days ago - Stoke Therapeutics price target lowered to $58 from $60 at Canaccord - TheFly
- 8 days ago - Stoke Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Stoke Therapeutics Earnings release: Q2 2026 - Filings
- 8 days ago - Stoke Therapeutics Quarterly report: Q2 2026 - Filings
- 8 days ago - Stoke Therapeutics Slides: Q2 2026 - Filings
- 8 days ago - Stoke Therapeutics reports Q2 EPS (93c), consensus (78c) - TheFly
- 8 days ago - Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates - Business Wire